Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New gel may improve tear duct surgery outcomes

NCT ID NCT07504250

First seen Apr 01, 2026 · Last updated Jun 23, 2026 · Updated 15 times

Summary

This study tests whether using hyaluronic acid gel during tear duct surgery works as well as the standard drug mitomycin-C. About 36 adults with chronic blocked tear ducts will be randomly assigned to receive one of the two treatments during surgery. The goal is to see which leads to better tear drainage, fewer complications, and faster healing.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DACRYOCYSTITIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

hyaluronic acid (gel) and mitomycin-C (drug)

What this could lead to

If hyaluronic acid works as well as mitomycin-C, it could offer a safer option during tear duct surgery with fewer side effects.

What could go wrong

This is a small, early-phase trial with only 36 participants, so results may not apply to everyone. The study hasn't started yet, and the benefits over standard care are uncertain.

Conditions

The condition(s) this trial relates to.

chronic dacryocystitis dacryocystitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.